Showing results (111-120 of 159) with videos related to
Sort By:
Pageof 16
Journal of the American Academy of Dermatology|May 14, 2010
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trialRichard G Langley, Steven R Feldman, Chenglong Han, et al.JAMA Dermatology|May 14, 2015
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Robert E Kalb, David F Fiorentino, Mark G Lebwohl, et al.Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.The New England Journal of Medicine|July 9, 2015
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque PsoriasisKenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, et al.Journal of Drugs in Dermatology : JDD|February 6, 2025
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc AnalysesKenneth B Gordon, Joseph F Merola, Peter Foley, et al.The Journal of Investigative Dermatology|June 18, 2019
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 StudyKenneth B Gordon, April W Armstrong, Peter Foley, et al.The Journal of Dermatological Treatment|May 5, 2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasisAndrew Blauvelt, Kenneth B Gordon, Patricia Lee, et al.JAMA Dermatology|March 9, 2016
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical TrialsApril W Armstrong, Charles W Lynde, Sandy R McBride, et al.Journal of the American Academy of Dermatology|October 25, 2003
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized studyAlice B Gottlieb, Thomas B Casale, Ellen Frankel, et al.The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.Pageof 16